ketorolac has been researched along with Ovarian Neoplasms in 7 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ketorolac has a novel pharmacologic activity conferred by the R-enantiomer and R-ketorolac achieves sufficient levels in the peritoneal cavity to inhibit Rac1 and Cdc42, potentially contributing to the observed survival benefit in women who received ketorolac." | 2.80 | A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients. ( Adams, SF; Bedrick, E; Cook, L; Guo, Y; Hudson, LG; Kang, H; Kenney, SR; Lomo, L; Muller, CY; Oprea, TI; Romero, E; Rutledge, T; Sklar, LA; Wandinger-Ness, A; Wiggins, CL, 2015) |
| "Nefopam is a centrally-acting non-opioid analgesic, which has no effect on bleeding time and platelet aggregation." | 2.80 | A Randomized Clinical Trial of Nefopam versus Ketorolac Combined With Oxycodone in Patient-Controlled Analgesia after Gynecologic Surgery. ( Hwang, BY; Kim, E; Kim, HK; Kim, TK; Kwon, JY; Lee, DW, 2015) |
| "R-ketorolac treatment inhibited tumor Rac1 and Cdc42 activity with little impact on mRNA or protein expression of these GTPase targets." | 1.62 | The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo. ( Brayer, KJ; Dominguez, DR; Grimes, MM; Guo, Y; Hudson, LG; Kenney, SR; Wandinger-Ness, A, 2021) |
| "The indication for surgery was: endometrial cancer (n=82; 41%), ovarian cancer (n=5; 2." | 1.40 | The feasibility and safety of same-day discharge after robotic-assisted hysterectomy alone or with other procedures for benign and malignant indications. ( Barakat, RR; Calderon, B; Gardner, GJ; Lee, SJ; Leitao, MM; Mays, A; Nolan, S; Sonoda, Y, 2014) |
| "Eighty patients with advanced ovarian cancer (International Federation of Gynecologists and Obstetricians, stage IIIC and IV) undergoing surgery between January 2000 and March 2011 were studied." | 1.39 | The relationship between neuraxial anesthesia and advanced ovarian cancer-related outcomes in the Chilean population. ( Assel, M; Brañes, J; Cartagena, J; Echevarría, GC; Lacassie, HJ, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Grimes, MM | 1 |
| Kenney, SR | 3 |
| Dominguez, DR | 1 |
| Brayer, KJ | 1 |
| Guo, Y | 3 |
| Wandinger-Ness, A | 3 |
| Hudson, LG | 3 |
| Lacassie, HJ | 1 |
| Cartagena, J | 1 |
| Brañes, J | 1 |
| Assel, M | 1 |
| Echevarría, GC | 1 |
| Lee, SJ | 1 |
| Calderon, B | 1 |
| Gardner, GJ | 1 |
| Mays, A | 1 |
| Nolan, S | 1 |
| Sonoda, Y | 1 |
| Barakat, RR | 1 |
| Leitao, MM | 1 |
| Cook, L | 1 |
| Adams, SF | 1 |
| Rutledge, T | 2 |
| Romero, E | 2 |
| Oprea, TI | 1 |
| Sklar, LA | 2 |
| Bedrick, E | 1 |
| Wiggins, CL | 1 |
| Kang, H | 1 |
| Lomo, L | 1 |
| Muller, CY | 2 |
| Adams, S | 1 |
| Murray-Krezan, C | 1 |
| Prekeris, R | 1 |
| Hwang, BY | 1 |
| Kwon, JY | 1 |
| Lee, DW | 1 |
| Kim, E | 1 |
| Kim, TK | 1 |
| Kim, HK | 1 |
| Rosen, DM | 1 |
| Houghton, CR | 1 |
2 trials available for ketorolac and Ovarian Neoplasms
| Article | Year |
|---|---|
A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients.
Topics: Aged; cdc42 GTP-Binding Protein; Disease-Free Survival; Female; Gene Expression Regulation, Neoplast | 2015 |
A Randomized Clinical Trial of Nefopam versus Ketorolac Combined With Oxycodone in Patient-Controlled Analgesia after Gynecologic Surgery.
Topics: Adolescent; Adult; Aged; Analgesia; Analgesia, Patient-Controlled; Analgesics, Non-Narcotic; Analges | 2015 |
5 other studies available for ketorolac and Ovarian Neoplasms
| Article | Year |
|---|---|
The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo.
Topics: Animals; Apoptosis; Cell Proliferation; Cyclooxygenase Inhibitors; Female; Humans; Ketorolac; Mice; | 2021 |
The relationship between neuraxial anesthesia and advanced ovarian cancer-related outcomes in the Chilean population.
Topics: Aged; Anesthesia, Conduction; Anesthesia, Epidural; Anesthesia, General; Anti-Inflammatory Agents, N | 2013 |
The feasibility and safety of same-day discharge after robotic-assisted hysterectomy alone or with other procedures for benign and malignant indications.
Topics: Adult; Aged; Ambulatory Surgical Procedures; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies | 2014 |
R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis.
Topics: Allosteric Regulation; Aminoquinolines; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; cdc42 | 2015 |
Ketorolac.
Topics: Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Blood Coagulation Disorders; Contraindica | 1993 |